Change in the Management Board of BRAIN AG

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Personnel
07.05.2020 / 08:00
The issuer is solely responsible for the content of this announcement.

Change in the Management Board of BRAIN AG

Chief Financial Officer Manfred Bender is leaving the biotechnology company at the end of the current financial year. Lukas Linnig to become the new CFO.

Zwingenberg, Germany
07 May 2020

The biotechnology company B.R.A.I.N. Biotechnology Research and Information Network AG announces that Chief Financial Officer Manfred Bender will leave the company at his own request on 30 September 2020. Mr Bender will take on a new assignment and has therefore asked the Supervisory Board to terminate his contract prematurely. The Supervisory Board has complied with this request.

The new Chief Financial Officer will be Lukas Linnig, the current Head of Finance, Controlling and Legal. Linnig has worked for the company since April 2017 and he previously advised BRAIN as a consultant during the IPO.

Dr Georg Kellinghusen, Chairman of the Supervisory Board, says: "We regret Mr Bender's decision, but we respect it. We thank him for his great contribution and commitment to BRAIN AG. With Lukas Linnig, we have found a successor who knows the company extremely well. There is sufficient time for an orderly transition until Mr Bender leaves the company."

Adriaan Moelker, CEO BRAIN AG, commented: "Lukas Linnig has proven that he has all the skills for a strong CFO. I am very pleased to have him on the management board and I am confident that with Lukas' appointment we are taking an important step in building a strong future-orientated team."

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.com.

B.R.A.I.N.
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.com

Contact Investor Relations
Michael Schneiders
Phone: +49-(0)6251-9331-86
Mobil: +49-(0)172 7957319
Email: mis@brain-biotech.com

Media Contact
Dr. Stephanie Konle
Managing Associate Corporate Communications
Phone: +49-(0)6251-9331-70
Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
 

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)



07.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



Share this page